Five Prime starts dosing patients in FPA008 Phase I trial to treat rheumatoid arthritis

US-based biotechnology firm Five Prime Therapeutics has started dosing in its Phase I clinical trial of FPA008, a monoclonal antibody that inhibits colony stimulating factor-1 receptor (CSF1R), to treat patients with rheumatoid arthritis (RA).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news